Kornimate/medical-research-clean huggingface dataset:
predictors of success of iui in unexplained infertility

Conditions: Assisted Reproductive Techniques

Summary: superovulation will be conducted with 100 mg of oral clomiphene citrate (clomifene; young poong pharmaceutical, incheon, korea) for 5 days starting on day 3 of the menstrual cycle, followed by daily injection of 150 iu of human menopausal gonadotropin (hmg;menogon; ferringpharamceutical co, germany). when more than 2 dominant follicles reached a diameter of 17 mm or the urinary specimen showed positive results for luteinizing hormone (lh) surge, 5000 iu of hcg (pregnyl; organon, oss, the netherlands) was injected intramuscularly.

superovulation will conducted with 100 mg of oral clomiphene citrate (clomifene; young poong pharmaceutical, incheon, korea) for 5 days starting on day 3 of the menstrual cycle, followed by daily injection of 150 iu of human menopausal gonadotropin (hmg;menogon; ferringpharamceutical co, germany). when more than 2 dominant follicles reached a diameter of 17 mm or the urinary specimen showed positive results for luteinizing hormone (lh) surge, 5000 iu of hcg (pregnyl; organon, oss, the netherlands) was injected intramuscularly. successful pregnancy after iui was confirmed by ultrasound as one or more visible gestational sacs in the uterine cavity.

Eligibility criteria:
inclusion criteria: * these patients had at least 1 tube patent * there were no significant intrauterine or pelvic abnormalities demonstrated on pelvic-abdominal ultrasonography, hysteroscopy, and/or laparoscopy * serum follicular stimulating hormone (fsh) level of12 miu/ml or less exclusion criteria: * a woman's age of more than 40 years, * ovarian cyst detected in the ultrasound examination * uterine lesions such as submucosal leiomyoma, and a previous diagnosis of moderate to severe pelvic endometriosis. * women with body mass index \> 35 kg/m2, * pcos/anovulatory patients * signs of hyperandrogenemia

Keywords: iui pregnancy rate predictors
expanded access to nanopac

Conditions: Locally Advanced Pancreatic Carcinoma; Prostate Cancer; Lung Cancer

Summary: nanology may consider offering expanded access to nanopac for patients who do not meet the enrollment criteria of clinical trials in progress.


Eligibility criteria:
inclusion criteria: - exclusion criteria: -
a randomized phase 3 trial of pemetrexed and cisplatin versus gemcitabine and cisplatin in patients with locally advanced or metastatic non small cell lung cancer

Conditions: Non Small Cell Lung Carcinoma

Summary: this study is a randomized phase 3 study comparing pemetrexed and cisplatin combination to gemcitabine and cisplatin for the treatment of non small cell lung cancer (ncslc). gemcitabine plus cisplatin is currently the standard of care for nsclc. it is thought that pemetrexed plus cisplatin may be as effective and may have fewer side effects than the standard of care.


Eligibility criteria:
inclusion criteria: * diagnosis of nsclc stage iiib not amenable to curative treatment or stage iv. * no prior chemotherapy for lung cancer. * patients must have at least one uni-dimensionally measurable lesion. * prior radiation therapy to less than 25% of bone marrow, whole pelvis not allowed. radiation must be completed at least 4 weeks prior to study enrollment. exclusion criteria: * treatment with any drug within the last 30 days that has not received regulatory approval. * serious cardiac condition. * serious medical disorder in addition to nsclc that would make it difficult for the patient to complete the study. * inability or unwillingness to take folic acid or vitamin b12 supplementation. * presence of fluid retention that cannot be controlled by drainage.
interpretation of serological tests in the diagnosis of celiac disease: anti-deamidated gliadin peptide antibodies revisited

Conditions: Celiac Disease

Summary: celiac disease is an autoimmune disorder characterized by a chronic inflammation of the small bowel mucosa, triggered by the ingestion of gluten-containing grains. the diagnosis of celiac disease was initially based on duodenal biopsies obtained from upper endoscopy. since 1990, the availability of serological tests has contributed to a different perception of the disease. serological testing is now considered fundamental for celiac disease screening, even if duodenal biopsies remain the gold standard. celiac markers usually include anti-tg2 antibodies, anti-endomysium antibodies, anti-gliadin antibodies and anti-reticulin antibodies. recently, several studies showed that deamidated products of gliadin may enhance t-cell stimulatory activity and improve the reactivity of anti-gliadin antibodies. thus, detection of anti-deamidated gliadin peptide antibodies has been introduced into the wide spectrum of serological tests for celiac disease.

the aim was to assess the clinical relevance of anti-deamidated gliadin peptide antibodies compared with the other common celiac markers.

Eligibility criteria:
inclusion criteria: - patients attending the reims university hospitals, for whom serological tests for celiac disease were prescribed between 1 april 2012 to 31 december 2014

Keywords: celiac disease serological tests anti-deamidated gliadin peptide antibodies
a study to assess the safety and effectiveness of pridopidine compared to placebo in the treatment of levodopa-induced dyskinesia in patients with parkinson's disease

Conditions: Parkinson Disease

Summary: this is a multicenter, randomized, three-arm, parallel-group, double-blind, placebo-controlled, study to evaluate the efficacy, safety and pharmacokinetics (pk) of pridopidine vs. placebo for the treatment of levodopa induced dyskinesia (lid) in patients with parkinson disease.


Eligibility criteria:
inclusion criteria: * provides signed informed consent form. * has clinical diagnosis of parkinson's disease (pd). * has levodopa-induced dyskinesia (lid). * patient and/or study partner must demonstrate ability to keep accurate home diary of pd symptoms. * has stable anti-pd treatments for at least 28 days prior to start of study treatment and kept constant throughout study. * all routine and allowed prescription/non-prescription medications and/or nutritional supplements taken regularly must be at stable dosage for at least 28 days prior to start of study treatment and maintained throughout study. exclusion criteria: * diagnosis of atypical parkinsonism. * treatment with dopamine blocking drugs. * history of surgical intervention related to pd, such as deep brain stimulation. * history of severe depression, psychosis or hallucinations within 6 months prior to screening; active suicidal ideation; or suicidal attempt within 5 years prior to screening. * history of certain cancers within 5 years prior to screening. * significant cardiac event within 12 weeks prior to baseline or history of certain cardiac arrhythmias. * history of epilepsy or seizures within 5 years prior to screening. * females who are pregnant or breastfeeding. * sexually active female patients who are not surgically sterile or at least 2 years postmenopausal prior to screening, and who do not agree to utilize a highly effective hormonal method of contraception in combination with a barrier method, from screening until at least 4 weeks after completion of study treatment. * male patients not using highly effective contraception or not agreeing to continue highly effective contraception until at least 90 days after the completion of study treatment. * treatment with any investigational product within 30 days of screening or plans to participate in another clinical study assessing any investigational product during the study. other protocol-defined inclusion/exclusion criteria could apply.

Keywords: levodopa dyskinesia
tranexamic acid effect in pediatric

Conditions: Tranexamic Acid Effect in Pediatric Polytraumatized Patients

Summary: the study will compare mortality and blood transfusion amounts among severely polytraumatized pediatrics who did or did not receive tranexamic acid within 3 h of injury, based on injury severity score (iss) and indicators of coagulopathy and fibrinolysis.

trauma is a leading cause of mortality in the pediatric population. in 2008, the american academy of pediatrics noted that trauma accounts for more deaths than all other causes combined . bleeding remains the most preventable cause of death after trauma. a major recent advance was the recognition that coagulation defects are greatly responsible for the disproportional mortality caused by bleeding. managing coagulation defects has become a forefront issue in trauma and novel strategies proposed include hemostatic resuscitation, adoption of massive transfusion protocols and other innovations , most with little evidence to support them. the exception is the proposal to administer tranexamic acid (txa) to bleeding adult trauma patients. to date, no medical treatment has been shown to reduce mortality in the setting of pediatric trauma; however, this evidence does exist in adults. bleeding and coagulopathy due to trauma are associated with mortality in both adults and children. clinical research has demonstrated a reduction in trauma-related mortality with early use of txa in adult patients in both civilian and military settings . in adult patients with hemodynamic instability and ongoing bleeding, txa is expected to save 1 in 67 lives . there is no scientific or biological reason to suggest that a similar mortality benefit will not be seen in pediatric trauma. the investigators feel the incorporation of txa into pediatric trauma management has the potential to also significantly reduce mortality in children and youths, without increasing adverse events. this review explores the hematologic differences and similarities between injured children and adults, and the idea that txa may be a novel and promising treatment in pediatric hemorrhagic trauma despite the current lack of evidence for its use in this setting. txa is an antifibrinolytic that reversibly binds to plasminogen at the lysine binding site, thus preventing the binding of plasmin (ogen) to fibrin and the subsequent degradation of fibrin . it is a generic, inexpensive medication used to prevent fibrin breakdown and reduce bleeding in various clinical settings (including orthopedic and cardiovascular surgery, post-partum hemorrhage, gastrointestinal hemorrhage, epistaxis, certain ophthalmologic conditions and other obstetric/gynecologic emergencies)

Eligibility criteria:
inclusion criteria: 1. iss ≥ 16 2. age 2-18 years 3. both genders 4. polytraum a exclusion criteria: 1. age \ 18 years 2. period from injury to admission \>6 hours 3. iss\<16 4. comorbidity with bleeding disorder, malignancy. 5. patients receiving anticoagulant drugs.

Keywords: tranexamic acid effect polytrauma pediatric
development and application of a musical game for motor rehabilitation

Conditions: Health People; Survivors of Stroke

Summary: the aim of this study is to develop, adapt a musical game for residents of ram, and evaluated the usability and correlation between this game with the improvement of motor coordination in short time.


Eligibility criteria:
inclusion criteria: * health people * survivors of stroke exclusion criteria: * dementia * visual defict * people who already knows how to play piano

Keywords: music intervention rehabilitation stroke motor coordination adults
blood sample analysis in predicting overall survival in patients with recurrent or metastatic head and neck cancer

Conditions: Head and Neck Cancer

Summary: rationale: studying samples of blood in the laboratory from patients with cancer may help doctors learn more about changes that occur in dna and identify biomarkers related to cancer. it may also help doctors predict how patients will respond to treatment. purpose: this research study is looking at blood sample analysis in predicting overall survival in patients with recurrent or metastatic head and neck cancer.

objectives: * to validate the mass spectrometry profile that is predictive of survival benefit in patients with recurrent or metastatic head and neck squamous cell carcinoma treated with egfr inhibitors. outline: plasma and serum samples are analyzed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and classified according to prognosis ("good" vs "poor") using a previously developed predictive algorithm.

Eligibility criteria:
disease characteristics: * diagnosis of recurrent or metastatic head and neck squamous cell carcinoma * meets 1 of the following criteria: * enrolled on clinical trial ecog-e3301 and previously treated with irinotecan hydrochloride and docetaxel * enrolled on clinical trial vu-vicc-hn-0501 and previously treated with docetaxel and bortezomib * plasma and serum samples available for analysis patient characteristics: * not specified prior concurrent therapy: * see disease characteristics

Keywords: recurrent squamous cell carcinoma of the hypopharynx stage iv squamous cell carcinoma of the hypopharynx stage iv squamous cell carcinoma of the larynx stage iv verrucous carcinoma of the larynx recurrent squamous cell carcinoma of the larynx recurrent verrucous carcinoma of the larynx recurrent squamous cell carcinoma of the lip and oral cavity stage iv squamous cell carcinoma of the lip and oral cavity recurrent verrucous carcinoma of the oral cavity stage iv verrucous carcinoma of the oral cavity metastatic squamous neck cancer with occult primary squamous cell carcinoma recurrent metastatic squamous neck cancer with occult primary recurrent squamous cell carcinoma of the nasopharynx stage iv squamous cell carcinoma of the nasopharynx recurrent squamous cell carcinoma of the oropharynx stage iv squamous cell carcinoma of the oropharynx recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity stage iv squamous cell carcinoma of the paranasal sinus and nasal cavity recurrent salivary gland cancer salivary gland squamous cell carcinoma stage iv salivary gland cancer
high resolution optical imaging of barrett's esophagus using nvision volumetric laser endomicroscopy (vle)

Conditions: Barrett's Esophagus

Summary: the primary objective of this clinical trial is to evaluate the performance of the nvision volumetric laser endomicroscopy (vle) system to visualize subsurface tissue in subjects undergoing esophagogastroduodenoscopy (egd) and to identify work-flow and training implications for introducing this new imaging modality.


Eligibility criteria:
inclusion criteria: * males and females over the age of 18 years. * patients with either suspected be presenting for endoscopy or patients with documented be presenting for follow-up endoscopy likely to require a biopsy or patients presenting for endoscopy for non-be related conditions other than esophageal varices. * ability to provide written, informed consent. * females who are able to become pregnant, are willing to take a pregnancy test. exclusion criteria: * patients on anticoagulation undergoing high risk procedures in accordance to american society for gastrointestinal endoscopy (asge) guideline for the management of antithrombotic agents for endoscopic procedures (2009). * patients with esophageal varices that preclude biopsies. * presence of an esophageal mass that precludes full distention of the balloon from the nvision balloon guide sheath. * patients with esophageal strictures that would prevent adequate expansion of the balloon from the nvision balloon guide sheath. * patients with known inflammatory disease, esophageal tears or ulcers, which would prohibit full distention of the balloon from the nvision balloon guide sheath. * patients with known eosinophilic esophagitis. * patients that are pregnant. * patients with a history of hemostasis disorders.
study of the clinical efficacy of autologous sct in patients with critical limb ischemia

Conditions: Critical Limb Ischemia

Summary: phase ii prospective study of the clinical efficacy of autologous sct in patients with critical limb ischemia

phase ii prospective study of the clinical efficacy of autologous sct in patients with critical limb ischemia

Eligibility criteria:
inclusion criteria: * patients with critical limb ischemia exclusion criteria: * patients with other than critical limb ischemia

Keywords: critical limb ischemia
genetic research on high myopic individuals in northern china

Conditions: High Myopia

Summary: hm, which can dramatically cripple the eyesight of those affected, is a rampant ophthalmic disorder around the globe. it is in recent years that substantial studies covering the relationship between distinct variations and hm susceptibility sprang expeditiously. however, these studies have not yielded sufficiently credible and universally significant conclusions. consequently, the study is conducted by including hm subjects residing in northern china to explicitly illustrate this issue.

as a serious pattern of myopia, high myopia (hm) generally refers to a condition where the spherical equivalent (se) refraction exceeds -6.00 diopters (d) or the axial length (al) is longer than 26.00 mm. abundant studies have indicated the strong correlation of hm with multiple vision-threatening ophthalmic diseases, including rhegmatogenous retinal detachment, retinoschisis, retinochoroid atrophy and open-angle glaucoma. it is reported that the worldwide prevalence of hm has surpassed over 2.9% in recent years. and a study on subjects living in minnesota from the 1960s to the 2010s demonstrates that the data has progressively increasing from 2.8% to 8.3%, which is not related with gender or race, although no evident significance has yet been proved in some groups. what's worse, it is speculated that hm patients are expected to account for 9.8% of the global population by 2050, which will gravely hinder the progress of social development. as a result, it is of profound implications to explore the pathogenesis of hm and the prospective therapeutic or remedial strategies. what has been universally acknowledged is that both environmental and genetic factors matter much in the onset and exacerbation of myopia, with the latter particularly predominating in the etiology of hm. accordingly, discussing the causation of hm from heredity version is likely to be the most promising research field, which is just the researchers' interest at the present.

Eligibility criteria:
inclusion criteria: * hm participants are characterized by al ≥ 26.00 mm or se ≤ -6.00 d in at least one eye. exclusion criteria: * individuals with other ocular or systemic connective tissue diseases were excluded.
chronic loose stools following right-sided hemicolectomy for colon cancer and the association with bile acid malabsorption and small intestinal bacterial overgrowth using a novel sampling device

Conditions: Colon Cancer

Summary: the goal of this clinical research study is to learn about gastrointestinal symptoms in participants who have undergone sc or rc and their impact on the quality of life of these participants.

to estimate the microbiota and bile acid profiles at multiple levels of the small intestine and proximal neo-colon in patients after rc and participants after sc.

Eligibility criteria:
inclusion criteria: * both men and women of all races and ethnic groups are eligible for this trial who meet the above criteria. exclusion criteria: * children will not be enrolled in this study. * pregnant women will not be enrolled in this study. * cognitively impaired subjects will not be enrolled in this study.
pilot study for the use of photodynamic therapy in the treatment of seborrheic dermatitis

Conditions: Seborrheic Dermatitis

Summary: the purpose of this study is: 1. to determine the efficacy of photodynamic therapy (pdt) in the treatment of seborrheic dermatitis. 2. to determine how pdt alters the skin microbiome in subjects with seborrheic dermatitis before and after treatment. 3. to determine how pdt alters sebum secretion rates in subjects with seborrheic dermatitis before and after treatment. the researchers hypothesize that pdt will be efficacious in the treatment of seborrheic dermatitis.

this pilot project investigates the use of pdt may be useful in the treatment of seborrheic dermatitis based on the following: the malassezia spp is capable of forming biofilms, 2) pdt has been shown to be effective against malassezia spp pdt can break up bioflims of both bacterial and fungal origin and benzoyl peroxide, a prooxidant treatment similar to pdt, has been shown to be effective in the treatment of seborrheic dermatitis.

Eligibility criteria:
inclusion criteria: * healthy subjects 18 years or older with seborrheic dermatitis of the face will be included. exclusion criteria: * subjects who are taking systemic corticosteroids (at doses of prednisone greater than or equal to 5 mg daily), antibiotics (po, im or iv) or using topical anti- fungals, steroids, antibiotics, permethrin, or calcineurin inhibitors within 2 weeks prior to the study will be excluded. * the exclusion criteria will also include the presence of other untreated inflammatory conditions (such as lupus, atopic dermatitis, or psoriasis) or untreated malignancies on the face (including skin cancers such as basal cell carcinoma, squamous cell carcinoma and melanoma). * any subjects with known or suspected hypersensitivity to any constituent of the study medication or a history of photosensitivity due to conditions such as lupus erythematosus and porphyria will be excluded. * subjects who have had photodynamic therapy (pdt) to the face for any reason within the past year will be excluded as well. * adults unable to consent, individuals under the age of 18, pregnant or breastfeeding women and prisoners will be excluded from the study.
a multi-center study of the effect of orthokeratology on myopia progression

Conditions: Myopia

Summary: this is a prospective study to validate an algorithm for predicting the effect of orthokeratology on myopia progression in children from 8 hospitals in china.

orthokeratology (ortho-k) is thought to be an effective way to control the progression of myopia in children, but its effectiveness may vary among different individuals. the investigators therefore conducted a prospective, multi-center study to use an algorithm to predict the progression of myopia among chinese children wearing orthokeratology lenses.

Eligibility criteria:
inclusion criteria: * -6.0d≤ser≤-0.5d * astigmatism≤2.0d exclusion criteria: * contraindications of wearing ortho-k. * diagnosis of strabismus, amblyopia and other refractive development of the eye or systemic diseases. * currently involved in other clinical studies.
evaluation of a standard preterm infant formula fed to preterm infants in the hospital

Conditions: Pre-term Infants

Summary: the purpose of this study is to assess overall growth of preterm infants fed a reformulated preterm infant formula during hospitalization. all study products meet levels of nutrients for the infant population as specified in the infant formula act and all subsequent amendments.


Eligibility criteria:
inclusion criteria: * subjects eligible for study participation will satisfy the following criteria: * birth weight between 1000g -1800g * less than or equal to 34 weeks and 0 days gestational age at birth * appropriate for gestational age (aga) * singleton or twin births * infant is 21 days of age or less exclusion criteria: * infants with the following conditions prior to and/or at the time of study product initiation are not eligible for entry into the study: * expected to be transferred to another facility within 14 days * serious congenital abnormalities that may affect growth and development * intubated for ventilation at the time of study product initiation * grade iii or iv periventricular/intraventricular hemorrhage (pvh/ivh) * maternal incapacity, maternal drug or alcohol abuse during pregnancy or current abuse, or maternal treatment consistent with human immunodeficiency virus therapy * infant has a history of major surgery * asphyxia defined as progressive hypoxemia and hypercapnia with significant metabolic acidemia * confirmed necrotizing enterocolitis or confirmed sepsis * current use or planned use of probiotics * participation in another study that has not been approved